Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : ASK Vendit Off Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: nohalo who wrote (7477)	2/5/2000 12:26:00 PM
From: DOUG H	Respond to of 19374

DA, have fun on your vacation. Thanks for adding your views. Sounds like some D&D is paying off for you. FWIW Walkingshadow was the author of that piece I posted to you. He'll not mind my mentioning his name and will allow you to follow up with any questions you may have. The boy does know his beans. D.H.

To: nohalo who wrote (7477)	2/7/2000 6:37:00 AM
From: Walkingshadow	Respond to of 19374

DA, I don't think the situation is as rosy as you imply for many reasons. For now, suffice it to say that it is just not that simple, and it remains to be seen how this will play out. Myself, I suspect that the numbers of revascularizations will DECREASE over the next ten years, since the data which has been coming out recently indicate that there is little or no benefit to performing them on most patients. That is, they do not prolong life, or prevent heart attacks, again in most patients. The primary benefit of angioplasty/stenting is relief of symptoms, most often only temporarily. Medical therapy (and perhaps, on the horizon, gene therapy) will play a larger role in the future, IMHO. .....we have the makings of at least a three bagger, over the medium term. I do not think that the market has woken up to these facts yet, and hopefully this will take a few weeks, so that we can accumulate. I would agree. My experience with KING suggests that the party is just getting going for CORR. KING, like CORR, was a relatively small cap company which had positive research results which suddenly opened a potentially huge market to them. Look what happened after the HOPE trial results were presented in preliminary form at the end of August, then the press release about the New England Journal of Medicine article in early November: askresearch.com KING never looked back, and went from 18 or so pre-Barcelona to 25 or so the next week, then jumped to the mid-60's *over the space of 2 or 3 weeks* in November at the time of the NEJM news. I suspect the same thing will happen with CORR, and as others have pointed out, the TA is certainly consistent with a further runup. I would not be surprised to see this stock double this coming week, and triple by the end of the month (with maybe a short selloff or two mixed in). As always, JMVHO........ Walkingshadow